Cabaletta Bio的CABA-201在治疗没有严重副作用的自发免疫疾病方面显示出希望。 Cabaletta Bio's CABA-201 shows promise in treating autoimmune diseases with no serious side effects.

Cabaletta Bio 在 ACR Convergence 2024 上展示了其疗法 CABA-201 的积极数据，在狼疮和肌炎等自身免疫性疾病患者中显示出良好的安全性和有效性。 Cabaletta Bio presented positive data on its therapy CABA-201 at the ACR Convergence 2024, showing good safety and efficacy in patients with autoimmune diseases like lupus and myositis. 这种治疗是含有4-1BB的CD19-CAR T细胞治疗,对大多数病人没有产生严重的副作用,并导致B细胞耗竭,有可能实现无药物缓解。 The therapy, a 4-1BB-containing CD19-CAR T cell treatment, demonstrated no serious side effects in most patients and led to B cell depletion, potentially allowing for a drug-free remission. 该公司正在五次临床试验中测试CABA-201,并计划在2025年与林业发展局会晤,讨论今后的试验设计。 The company is testing CABA-201 in five clinical trials and plans to meet with the FDA in 2025 to discuss future trial designs.